Literature DB >> 18332908

The relationship between absolute lymphocyte count with PFS in patients with Hodgkin's lymphoma undergoing autologous hematopoietic cell transplant.

T Seshadri1, M Pintilie, A Keating, M Crump, J Kuruvilla.   

Abstract

Previous reports in Hodgkin's lymphoma (HL) patients undergoing autologous hematopoietic cell transplantation (AHCT) have demonstrated a significant association between the absolute lymphocyte count at day 15 (ALC-15) with survival. To evaluate this finding further, we analyzed 146 patients with relapsed/refractory HL who underwent AHCT to evaluate the relationship between lymphocyte counts at apheresis and at two time points (days 15 and 90) after AHCT with PFS. We found no association between the ALC-15 and the ALC-90 with PFS. We found lymphocyte counts at apheresis and disease sensitive to salvage chemotherapy were predictive of PFS. In conclusion, our study does provide some support for the theory that the immune system may be important in disease control but further and more detailed studies in this area are required.

Entities:  

Mesh:

Year:  2008        PMID: 18332908     DOI: 10.1038/bmt.2008.41

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Pretreatment T lymphocyte numbers are contributing to the prognostic significance of absolute lymphocyte numbers in B-cell non-Hodgkins lymphomas.

Authors:  Lajos Gergely; Andrea Váncsa; Zsófia Miltényi; Zsófia Simon; Sándor Baráth; Árpád Illés
Journal:  Pathol Oncol Res       Date:  2010-09-15       Impact factor: 3.201

2.  Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients.

Authors:  Raffaella Marcheselli; Alessia Bari; Tamar Tadmor; Luigi Marcheselli; Maria Christina Cox; Samantha Pozzi; Angela Ferrari; Luca Baldini; Paolo Gobbi; Ariel Aviv; Giuseppe Pugliese; Massimo Federico; Aaron Polliack; Stefano Sacchi
Journal:  Hematol Oncol       Date:  2016-10-28       Impact factor: 5.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.